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The contributions of hepatic glycogenolysis to fasting glu-
cose production and direct pathway to hepatic glycogen
synthesis were quantified in eight type 1 diabetic patients
and nine healthy control subjects by ingestion of 2H2O and
acetaminophen before breakfast followed by analysis of
urinary water and acetaminophen glucuronide. After over-
night fasting, enrichment of glucuronide position 5 relative
to body water (G5/body water) was significantly higher in
type 1 diabetic patients compared with control subjects,
indicating a reduced contribution of glycogenolysis to glu-
cose production (38  3 vs. 46  2%). Following breakfast,
G5/body water was significantly higher in type 1 diabetic
patients, indicating a smaller direct pathway contribution
to glycogen synthesis (47  2 vs. 59  2%). Glucuronide
hydrogen 2 enrichment (G2) was equivalent to body water
during fasting (G2/body water 0.94  0.03 and 1.02  0.06
for control and type 1 diabetic subjects, respectively) but
was significantly lower after breakfast (G2/body water
0.78  0.03 and 0.82  0.05 for control and type 1 diabetic
subjects, respectively). The reduced postprandial G2 levels
reflect incomplete glucose-6-phosphate–fructose-6-phos-
phate exchange or glycogen synthesis from dietary galac-
tose. Unlike current measurements of human hepatic
glycogen metabolism, the 2H2O/acetaminophen assay does
not require specialized on-site clinical equipment or per-
sonnel. Diabetes 55:2294–2300, 2006
Hepatic glycogen is the principal short-term re-serve for circulating glucose in humans andtherefore plays an important role in glucosehomeostasis. Patients with poorly controlled
type 1 diabetes accumulate poor hepatic glycogen stores
during feeding, and these sustain limited rates of endoge-
nous glucose production during fasting. Consequently, the
maintenance of fasting euglycemia in response to a drop in
blood glucose levels becomes more dependent on the
activation of gluconeogenesis by counterregulatory mech-
anisms. For many type 1 diabetic subjects this functions
poorly, thereby increasing the patient’s vulnerability to a
hypoglycemic episode. Thus, insufficient rates of hepatic
glycogen storage and hydrolysis may contribute to the
development of fasting hypoglycemia. Hepatic glycogen is
synthesized by two distinct processes: the classical direct
pathway from intact glucose units and an indirect pathway
involving 3-carbon intermediates such as pyruvate (1–3).
With current human tracer methodologies, true hepatic
indirect pathway activity is indistinguishable from Cori
cycle metabolism of glucose since 3-carbon intermediates
are common to both processes. Also, nonglucose precur-
sors such as glycerol or gluconeogenic amino acids can
feed the 3-carbon pool and contribute to indirect pathway
flux. In healthy subjects, the direct pathway accounts for
the bulk of hepatic glycogen synthesis (4,5), but in type 1
diabetic patients, its contribution is reduced to 50%
(6–8).
In type 1 diabetic patients, some key deficiencies of
hepatic glycogen fluxes can be restored by intensive
dietary and insulin therapy. After establishing good long-
term metabolic control as a result of tailored multiple
insulin injections, type 1 diabetic patients were able to
convert dietary carbohydrate to glycogen at comparable
rates to healthy subjects (8). Also, hepatic glycogenolysis
rates and the fractional contribution of glycogenolysis to
endogenous glucose production after overnight fasting
were restored to normal values (8). However, this inter-
vention did not increase the fraction of glycogen synthe-
sized by the direct pathway to that of healthy control
subjects (8). These and other studies (6,9) demonstrate
that assessment of hepatic glycogen kinetics could be
useful for evaluating and guiding therapies of glycemic
control in type 1 diabetic patients. Currently, rates of
hepatic glycogen synthesis and hydrolysis are obtained by
observing the natural abundance 13C glycogen signal with
a whole-body magnetic resonance system (6,8,10–12).
While this method provides a direct assessment of hepatic
glycogen levels, it is only available in a few research
centers around the world. Measurement of direct and
indirect pathway activities involve the ingestion of 10 g
[1-13C]glucose in a breakfast meal and analysis of 13C-
enrichment in plasma glucose and urinary glucuronide
(13). The tracer is relatively expensive and both blood and
urine need to be collected.
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We present a practical and noninvasive method that
provides information on the direct/indirect pathway of
hepatic glycogen synthesis during feeding and the contri-
bution of glycogenolysis to endogenous glucose produc-
tion during fasting. The assay involves the oral
administration of deuterated water (2H2O) and acetamin-
ophen followed by the analysis of deuterium (2H) enrich-
ment of urinary acetaminophen glucuronide before and
after a breakfast meal (Fig. 1). Glucuronide is derived from
hepatic uridine diphosphate glucose (UDPG), the immedi-
ate precursor of glycogen synthesis (Fig. 2). As a result of
exchange between glucose-6-phosphate (G6P) and fruc-
tose-6-phosphate (F6P) catalyzed by G6P-isomerase (14),
UDPG synthesized via the direct pathway will be enriched
with 2H in position 2. If G6P-F6P exchange is complete,
hydrogen 2 of UDPG will be enriched to the same level as
body water. UDPG synthesized via 3-carbon precursors
(i.e., indirect pathway or gluconeogenesis) will be en-
riched in both 2 and 5 positions due to exchange/addition
of water and metabolite hydrogens at triose and hexose
phosphate levels. Therefore, the contribution of the direct
relative to the indirect pathways of hepatic glycogen
synthesis can be estimated by the ratio of glucuronide
2H-enrichment in position 5 relative to position 2 (G5/G2).
During fasting, when glycogen is hydrolyzed to glucose,
there remains a residual flux through UDPG and glucu-
ronidation pathways. Due to the rapid interchange of
hepatic G6P, glucose-1-phosphate (G1P), and F6P pools,
the 2H-enrichment pattern of G6P diverted for glucuronide
synthesis is equivalent to that of plasma glucose. Glyco-
genolysis will generate hexose-P with 2H-enrichment in
position 2 only, while gluconeogenesis will generate hex-
ose-P enriched in positions 2 and 5. Therefore, the fraction
of glucose output derived from glycogenolysis can be
estimated from G5/G2 of the fasting glucuronide (15).
Glucuronide G5/G2 values can be conveniently determined
by 2H nuclear magnetic resonance (NMR) following deri-
vatization to monoacetone glucose (MAG) (15). Where
applicable, the use of menthol in the form of peppermint
oil as the glucuronidation probe can further simplify the
procedure since urinary menthol glucuronide can be ana-
lyzed directly after a simple purification procedure (16).
RESEARCH DESIGN AND METHODS
Nine healthy subjects (3 women and 6 men, age 21  1 years, weight 67  13
kg, HbA1c [A1C] 4.9  0.2%) and eight type 1 diabetic subjects (3 women and
5 men, age 20  1 years, weight 65  8 kg, A1C 8.1  1.6%, mean duration of
diabetes 10  2 years) were studied. Exclusion criteria included use of
tobacco, antihypertensive medications, systemic steroids, and renal or hepatic
dysfunction. Subjects were admitted into the hospital and began fasting at
2000 following a standard dinner. At 0200, each subject ingested 1,000 mg
acetaminophen and 3.0 g/kg body water of 2H2O as a 40% solution in
noncarbonated spring water (350 ml total volume) imbibed over 15–20 min.
For the remainder of the study, the subject drank water containing 0.3% 2H2O
to maintain body water enrichment. After collection of urine from 0600 to
0800, the subject ingested a standardized breakfast conforming to American
Diabetes Association guidelines (720 kcal, 60% carbohydrate, 20% protein, and
20% fat) and 500 mg acetaminophen. Subjects voided at 1000, and urine was
collected from 1000 to 1200.
Sample processing and NMR spectroscopy. Acetaminophen glucuronide
was converted to MAG as described (17). Proton-decoupled MAG 2H NMR
spectra were acquired at 11.75 T with a Varian Unity 500 system equipped with
a 5-mm broadband probe (Varian, Palo Alto, CA). Spectra were obtained at
50°C without field-frequency lock with a 90° pulse angle, a sweep width of 10
ppm, an acquisition time of 1.6 s, and no pulse delay. Between 8,000 and 30,000
free induction decays were acquired per sample for collection times of
3.5–13.3 h. The summed free induction decays were processed with 0.5–1.0 Hz
line-broadening before Fourier transform. Fully relaxed 1H NMR spectra were
obtained under the same conditions with presaturation of the acetonitrile
signal. A pulse width of 45°, acquisition time of 3 s, and a delay of 16 s were
used. For each 1H spectrum, 4–16 free induction decays were acquired. 2H
enrichment of urine water was analyzed by 2H NMR as previously described
(18). All NMR spectra were analyzed using the curve-fitting routine supplied
with the NUTS PC-based NMR spectral analysis program (Acorn NMR,
Fremont, CA).
Quantification of glucuronide hydrogen 2 absolute 2H-enrichment. Abso-
lute 2H enrichment of glucuronide hydrogen 2, hereafter defined as G2, was
obtained by calculating the moles of 1H and 2H nuclei in position 2 of MAG.
The amount of [2-1H]MAG was obtained from the ratio of dimethylformamide
(DMF) methyl (1H DMF) and MAG hydrogen 2 (1H MAG) proton signals
multiplied by the amount of 1H DMF present (9.58 mol) and corrected for the
1:3 stoichiometry of the MAG and DMF methyl protons (equation 1 below).
Likewise, the amount of [2-2H]MAG was obtained from the ratio of DMF
methyl (2H DMF) and the MAG hydrogen 2 (2H MAG) deuterium signals
multiplied by the amount of 2H DMF present (0.46 mol) and the 1:3
stoichiometry factor (equation 2 below). In addition, DMF 2H signals are
partially saturated under the NMR acquisition conditions due to long relax-
ation times (T1  2–4 s), while those of MAG are fully relaxed (T1  175–250
ms). To account for partial saturation, each 2H DMF methyl signal intensity
was multiplied by a correction factor, obtained by quantifying the change in
the DMF 2H signal intensity relative to that of a 3% [2-2H]MAG standard
obtained under ambient and fully relaxed conditions: 1) [2-1H]MAG (mol) 
9.58  0.333  (1H DMF/1H MAG); 2) [2-2H]MAG (mol)  0.46  0.333  (2H
DMF/2H MAG); 3) %2H enrichment of MAG hydrogen 2 (G2)  [2-2H]MAG/
([2-2H]MAG  [2-1H]MAG)  100.
G2 was calculated from the quantities of 1H and 2H as shown in equation
3. 2H fractional enrichment determinations were performed with both DMF
methyl signals and the mean of both values is reported.
Quantification of hepatic glycogen fluxes. From urine collected before
breakfast, the contribution of gluconeogenesis and glycogenolysis to hepatic
glucose production was estimated from the enrichment of glucuronide
position 5 (G5) relative to that of body water (G5/body water) as shown by
equations 1 and 2: 4) glucose production from glycogenolysis (%)  1-(G5/
body water)  100 and 5) glucose production from gluconeogenesis (%) 
FIG. 1. 2H2O and acetaminophen administration and urine collection
protocol.
FIG. 2. Hepatic glucose-glycogen fluxes and sampling by acetamino-
phen glucuronide (AG) during fed and fasted states.
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(G5/body water) 100. G5 was derived by multiplying G2 by the ratio of signal
5 to signal 2 of the MAG 2H NMR spectrum.
From urine collected after breakfast, the contribution of direct and indirect
pathways to hepatic glycogen synthesis was estimated from G5/body water, as
shown by equations 1 and 2: 6) glycogen synthesis via direct pathway (%) 
1-(G5/body water) 100 and 7) glycogen synthesis via indirect pathway (%)
(G5/body water)  100.
Unless indicated otherwise, all data are presented along with means and
SDs. Differences between means of experimental data obtained from healthy
and type 1 diabetic subjects were evaluated by a two-tailed, heteroscedastic
Student’s t test. P values of 0.05 were considered significant.
RESULTS
For both subject groups, a constant level of body water
enrichment was achieved before and after the breakfast
meal (Table 1). Also, enrichment of glucuronide hydrogen
2 (G2) during fasting approached that of body water
indicating quantitative incorporation of body water 2H into
position 2 of G6P. For the postprandial glucuronide of
both study groups, G2 was significantly lower than that of
the fasting glucuronide and was only 80% of body water
enrichment.
2H NMR spectra of MAG derived from acetaminophen
glucuronide generated well-resolved 2H MAG resonances
with high signal-to-noise ratios (Fig. 3). Each signal repre-
sents 2H-enrichment in a specific position of glucuronide
and the signal intensities are proportional to the enrich-
ment of 2H at that site. 2H-NMR spectra derived from the
prebreakfast glucuronide of healthy control subjects were
consistent with those reported in a study of overnight-
fasted healthy control subjects (15). The position 2 signal
had the highest intensity, reflecting the near-equivalent
2H-enrichment of UDPG hydrogen 2 and body water. Other
MAG 2H-signals corresponding to positions 3, 4, and 5 of
glucuronide were less intense, indicating dilution of 2H-
enrichment at these sites by G6P derived from unlabeled
hepatic glycogen. The intensity of signal 5 relative to signal
2 corresponds to the 2H-enrichment ratio of positions 5
and 2 (G5/G2) and provides an estimate of the relative
contribution of gluconeogenesis and glycogenolysis to
G6P synthesis (10,19). While the mean G5/G2 was signifi-
cantly higher for the type 1 diabetic group compared with
healthy control subjects, the ranges (0.52–0.70 for type 1
diabetic and 0.49–0.61 for healthy control subjects) over-
lapped considerably. For both healthy and type 1 diabetic
subjects, estimates of glycogenolysis derived from G5/
body water enrichment were equal to those obtained from
that of glucuronide G5/G2 as expected from the equiva-
lence of G2 and body water enrichment. As was previously
observed with plasma glucose enrichment distributions
from 2H2O in healthy subjects and cirrhotic patients, the
hydrogen 4 and 5 signals of MAG had equal intensities
indicating that G6P hydrogens 4 and 5 were enriched to
equivalent levels from 2H2O (20). Also, hydrogen 3 enrich-
ment was significantly lower than hydrogen 5 (0.09  0.01
vs. 0.14  0.01, P  0.0002 for control subjects; and 0.10 
0.01 vs. 0.16  0.01, P  0.0003 for type 1 diabetic
patients), indicating that exchange of 1R-dihydroxyac-
etone phosphate (the precursor of G6P hydrogen 3) with
body water was incomplete. 2H NMR signals were not
observed for the six pro-R and six pro-S hydrogens of MAG
since these are obtained from the reduction step in the
derivatization procedure and are therefore not enriched
above background level (15). Estimates of fractional glu-
coneogenesis and glycogenolysis derived from fasting
G5/G2 of healthy subjects indicate that half (46  2%) of
fasting glucose production was derived from glycogenoly- TA
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sis. These observations are in good agreement with both
gas chromatograph–mass spectrometer and NMR mea-
surements of healthy individuals given similar dosages of
2H2O and fasted for similar intervals (20–22). In type 1
diabetic patients, glycogenolysis contributed a signifi-
cantly smaller fraction of fasting glucose production (38 
2%). This observation is consistent with in vivo 13C MR
measurements that showed a reduced contribution of
glycogenolysis to endogenous glucose production in rest-
ing type 1 diabetic subjects compared with healthy control
subjects (9).
For both subject groups, glucuronide obtained after
breakfast had a 2H-relative enrichment distribution that
was remarkably similar to that obtained before breakfast,
as shown by the examples in Fig. 3. For any given subject,
fed and fasting G5/G2 were closely matched and the
relative 2H-signal intensities of hydrogens 3, 4, and 5 of fed
and fasted glucuronide were almost identical. For the type
1 diabetic group, enrichment of glucuronide hydrogen 1
relative to hydrogen 2 (G1/G2) tended to be higher in the
fed compared with fasted state (0.84 0.11 vs. 0.74 0.09,
P  0.07), whereas for healthy control subjects, G1/G2
ratios of fed and fasted glucuronide were not different
(0.73  0.04 and 0.74  0.06, respectively).
Postabsorptive glucuronide G5/body water enrichment
ratios were significantly different between healthy and
type 1 diabetic subjects (see Table 1), indicating differ-
ences in the fractional contributions of direct and indirect
pathways to hepatic glycogen synthesis. For healthy sub-
jects, the majority of hepatic glycogen (59  2%) was
synthesized via the direct pathway, while in type 1 diabetic
patients, the direct pathway accounted for a significantly
smaller fraction of glycogen synthesis (47  2%, P  0.05
versus control subjects). The G5/body water enrichment
ratio was significantly less than G5/G2 under fed condi-
tions, due to G2 being only 80% that of body water. From
this information, the direct pathway contribution can be
resolved into two components: one where the hexose
moiety underwent G6P-F6P exchange en route to glycogen
synthesis and the other where this exchange did not occur.
The fraction of glycogen synthesized via these routes and
from the indirect pathway is shown in Fig. 4. Our results
suggest that for both subject groups, a sizable fraction of
direct pathway flux (37  3% for control and 38  5% for
type 1 diabetic patients) did not participate in G6P-F6P
exchange.
DISCUSSION
Quantifying sources of fasting glucose production by
2H2O-glucuronide analysis. Steady-state enrichment of
plasma glucose or glucuronide from ingested 2H2O is the
result of three processes. First, the equilibration of in-
gested 2H2O with bulk body water; second, the various
exchange or addition reactions that transfer 2H from body
water to precursor metabolites; and third, the turnover of
the product metabolite pool. 2H2O is equilibrated with
body water at 3–4 h (22) and the glucuronide was sampled
from 4 to 6 h after ingestion, so the body water 2H is
assumed have reached constant enrichment during the
time that the initial glucuronide sample was harvested.
While the exchange reactions that transfer 2H from water
to metabolic intermediates are relatively rapid, there is the
possibility of discrimination against 2H incorporation into
certain metabolite sites due to kinetic isotope effects (23).
Although incorporation of 2H into position 2 of glyceral-
dehyde-3-P (the precursor for G6P hydrogen 5) does not
experience isotopic discrimination (24), the rate of incor-
poration of 2H into position 2 of G6P via phosphoglucoi-
somerase is slower than that of 1H due to a primary kinetic
isotope effect (23). However, extensive equilibration of
G6P and F6P minimizes any isotopic discrimination
against the incorporation of 2H into position 2 (23).
Compared with plasma glucose, hepatic UDPG and gluc-
uronide are small metabolite pools that are rapidly turning
over. As a result, glucuronide reaches isotopic steady-state
(defined as the time for the glucose or glucuronide hydro-
gen 2 enrichment to reach a constant level) at an earlier
time than plasma glucose. Insulin resistance or diabetes
may result in an increased plasma glucose pool size,
possibly prolonging the time for plasma glucose to reach
steady-state enrichment. Plasma glucose can be sampled
instantaneously, but with glucuronide there is a 30- to
60-min lag time between its formation in the liver and
clearance into urine (25). Also, glucuronide is sampled
over a period of several hours during which G5/G2 ratios
may alter significantly due to changes in physiology, for
example the depletion of hepatic glycogen during fasting.
In healthy subjects who were given 2H2O and fasted
overnight, the plasma glucose hydrogen 5–to–hydrogen 2
enrichment ratio (H5/H2) increased by 10% between the
12th and 14th hour of fasting (22). In another 2H2O study,
plasma glucose H5/H2 increased by 14% in healthy sub-
jects and 13% for type 2 diabetes patients from the 14th to
the 16th hour of fasting (10). Direct and indirect pathway
contributions to glycogen synthesis also change over the
initial few hours after feeding (4,7). In light of these
observations, a 2-h urine collection time represents a
compromise between obtaining sufficient urinary glucuro-
nide for NMR analysis and providing reasonable temporal
resolution for defining fractional gluconeogenesis or gly-
cogen synthesis in relation to the time of fasting or
feeding.
Glycogen metabolism and glucuronide synthesis are
both located in the pericentral region of the hepatic lobule,
whereas gluconeogenic activity is highest in the periportal
FIG. 3. 2H NMR spectra of the monoacetone glucose derivative of
acetaminophen glucuronide with the position 5 and position 2 NMR
signals indicated by the number above each signal. Also shown are the
G5/G2 enrichment ratios calculated from the relative intensities of
these signals. Spectra were obtained from a healthy control subject
(CON) before and after breakfast (fasting and fed, respectively).
Below is the corresponding fasting and fed NMR spectra from a patient
with type 1 diabetes (T1D).
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region (26,27). On this basis, G1P derived from glycogenoly-
sis might be expected to be more available for glucuronide
synthesis compared with glucose-1-phosphate derived
from gluconeogenesis, resulting in a higher fractional
contribution of glycogenolysis to glucuronide synthesis
compared with that for hepatic glucose production. In the
2H2O experiment, this would result in a glucuronide G5/G2
ratio that was less than that of plasma glucose. Other
mechanisms that could result in different glucuronide and
plasma glucose enrichments include glucose production
from extrahepatic tissues. To date, direct comparisons of
plasma glucose and glucuronide 2H-enrichments from
2H2O have been few but equivalent
2H-enrichment ratios
for the two metabolites were reported for healthy control
subjects (15). Also, the glucuronide G5/G2 ratios of
healthy subjects from this study are consistent with pre-
vious gas chromatograph–mass spectrometer and NMR
measurements of plasma glucose H5/H2 from healthy
subjects given 2H2O under similar conditions (14,15,20,22).
Comparison of 2H2O and glucose tracers for measur-
ing direct and indirect pathway contributions to
glycogen synthesis. Estimates of direct pathway contri-
butions using 13C, 14C, or 3H tracers have been made
during hyperglycemic clamp conditions where the glucose
tracer is infused into a peripheral vein and also during
mixed meals where the glucose tracer is ingested with the
meal. In each case, the specific activity or enrichment of
plasma glucose and urinary glucuronide are measured and
the extent of label dilution in glucuronide versus plasma
glucose (with corrections for tracer recycling) provides a
measure of direct and indirect pathways. When [1-13C]glu-
cose was ingested during a mixed meal, direct pathway
contributions of 49  7 and 30  8% were reported for
control and type 1 diabetic subjects, respectively (8). In a
study of healthy subjects that were given [1-13C]glucose by
infusion after a breakfast meal, direct pathway estimates
of 60–70% were reported (4). From the study of Stingl et al.
(28), where dilution of infused [5-3H]glucose in glucuro-
nide versus plasma glucose was measured, the direct
pathway accounted for 54–63% of glycogen synthesis in
healthy subjects under hyperglycemic clamp conditions.
Our direct pathway estimate of 59% for healthy subjects is
more closely matched to those measurements where the
glucose tracer was infused rather than where it was
ingested with the meal.
In the metabolic model representing the fed state (Fig.
2) it is assumed that glucose is the sole carbohydrate
substrate, exchange between G6P and F6P is complete,
and there is no significant glycogen cycling or transaldo-
lase activity. When these assumptions are unmet, esti-
mates of direct and indirect pathway contributions derived
from 2H2O are modified differently to those derived from
glucose tracers, as summarized in Table 2. [1-13C] or
[5-3H]glucose measurements are unaffected by G6P-F6P
exchange because this does not redistribute or dilute
either tracer. In contrast, the glucuronide 2H-enrichment
distribution from 2H2O is sensitive to the extent of G6P-
F6P exchange. If exchange is incomplete, G2 is decreased
relative to body water and to G5 resulting in an increased
G5/G2 ratio and an underestimate of the direct pathway
contribution. Under these conditions, G5/body water en-
richment provides correct estimates for direct/indirect
pathway contributions. Utilization of an alternative carbo-
hydrate source such as galactose will also modify flux
estimates from both 2H2O and labeled glucose tracers.
Galactose is metabolized to UDPG via galactose-1-P and
UDP-galactose. No 2H is incorporated from 2H2O into the
hexose skeleton during these steps. Therefore, this activity
will systematically dilute 2H-enrichment of all positions
resulting in reduced G2/body water and G5/body water
ratios but no modification of G5/G2. Therefore, to the
extent that galactose contributes to UDPG synthesis,
measurement of G5/body water enrichment will overesti-
mate the contribution of the direct pathway. With [1-13C]
or [5-3H]glucose, galactose metabolism will dilute the
enrichment or specific activity of UDPG, resulting in an
underestimate of direct pathway contribution. Glycogen
cycling will also modify glucuronide 2H-enrichment distri-
bution in positions 5 and 2 (28). Inflow of unlabeled
hexose units from glycogen hydrolysis results in a system-
atic dilution of 2H-enrichment in all sites except for position
2. Glycogen3G1P7G6P7F6P7 G6P7G1P3UDPG will
generate UDPG enriched in hydrogen 2 assuming com-
plete exchange between G1P, G6P, and F6P. Therefore,
both G5/G2 and G5/body water enrichment ratios are
reduced, resulting in an overestimate of the direct path-
way contribution to hepatic glycogen synthesis. With
[1-13C]glucose, glycogen cycling dilutes the label at the
level of UDPG resulting in an underestimate of the direct
pathway contribution to glycogen synthesis. This is also
true for the [5-3H]glucose tracer (28). Finally, transaldo-
lase activity exchanges the bottom triose unit of F6P with
glyceraldehyde-3-phosphate. This provides an additional
mechanism for enriching hydrogen 5 from 2H2O or for
depleting the specific activity of [5-3H]hexose, therefore
with both tracers, the direct pathway contribution is
underestimated (28). With [1-13C]glucose, this process
does not influence glucuronide C1 enrichment but may
slightly increase the enrichment of C6, resulting in a minor
underestimation of the direct pathway fraction.
We observed that enrichment of postabsorptive glucuro-
nide was significantly less than that of body water (i.e.,
G2/body water 0.8). That this could be an artifact of the
NMR measurement is unlikely since G2/body water ratios
of 1.0 were quantified from the fasting glucuronide. As
discussed above, UDPG synthesis from galactose and
incomplete G6P-F6P exchange could both contribute to
G2 being less that that of body water. The breakfast meal
contained a significant source of galactose in the form of
400 ml reduced-fat milk. Following release from lactose
and uptake into splanchnic blood, essentially all galactose
is metabolized in liver compared with only approximately
FIG. 4. Sources of hepatic glycogen synthesis in a group of healthy
control subjects and a group of type 1 diabetic patients (T1D) as
estimated from the fed glucuronide G5/G2 and G5/body water ratios.
The black portion represents the indirect pathway contribution, the
gray portion represents the contribution from direct pathway with
G6P-F6P exchange, and the white portion represents the contribution
from direct pathway with no G6P-F6P exchange. Data represent mean
values for each group, and the error bar represents the SE.
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one-fifth of the total glucose carbohydrate equivalents.
The amount of milk provided could supply sufficient
galactose to systematically dilute the hepatic UDPG en-
richment by at least 20% and account for the observed
G2/body water enrichment ratio. Four hundred milliliters
of reduced fat milk contains 20.8 g of lactose or 10.4 g
galactose for UDPG synthesis. The total breakfast carbo-
hydrate load was 113 grams, of which 103 grams were
glucose units. Assuming that 20 grams of glucose was
taken up by the liver and converted to UDPG, then the
contribution of UDPG flux from galactose could be as high
as 10.4/30.4  34%. However, similar G2/body water ratios
(0.83) were also found during a hyperglycemic clamp,
where glucose is the only carbohydrate source for hepatic
glycogen synthesis and UDPG synthesis from galactose is
negligible (28). These observations suggest that incom-
plete G6P-F6P exchange could also contribute to a re-
duced G2 enrichment. In support of this, rat hepatocytes
provided with glucose labeled with 3H and 14C in position
2 retained40% of 3H relative to 14C in glycogen indicating
that 40% of glucose did not undergo G6P-F6P cycling en
route to glycogen synthesis (29). This is in good agreement
with our estimate of the fraction of direct pathway flux
(37%) that did not experience G6P-F6P exchange. Poten-
tial mechanisms that could limit G6P-F6P exchange during
fed conditions include the preferential recruitment of G6P
derived from glucokinase by the glycogen synthesis path-
way (30,31). In contrast, fasting conditions favor more
complete exchange of G2 and body water because G6P
derived from glycogen is not preferentially converted to
glucuronide over G6P derived from gluconeogenesis.
Moreover, cycling of glucose and G6P provides additional
opportunity for 2H-incorporation by G6P-F6P exchange.
In conclusion, we demonstrate a practical and econom-
ical method for quantifying the sources of hepatic glucose
and glycogen synthesis in type 1 diabetic patients that can
be performed in a standard hospital setting. The analysis
reveals significant differences in these parameters be-
tween type 1 diabetic patients and healthy subjects and
this information may be highly relevant for assessing
glycemic control. These data are consistent with previous
measurements obtained by clinical 13C MR spectroscopy
and glucose tracers. Since it is does not require any
specialized clinical equipment or personnel, the 2H2O/
acetaminophen assay should make these measurements
available to a much wider clinical research community.
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